The associations between hypertension and the risks of long-term liver-related and other adverse clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were recently explored in the observational study by Zhou and coworkers1. However, a number of important unmeasured or insufficiently captured confounders that may substantially affect both the exposure of interest (ie, hypertension) and the outcomes were not accounted for in their observational study1.
The associations between hypertension and the risks of long-term liver-related and other adverse clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were recently explored in the observational study by Zhou and coworkers1. However, a number of important unmeasured or insufficiently captured confounders that may substantially affect both the exposure of interest (ie, hypertension) and the outcomes were not accounted for in their observational study1.